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Introduction
The broad category of neuromuscular diseases covers
conditions that involve the weakness or wasting of the
body muscles in human as well as in animal.
These problems may arise in the spinal cord, the
peripheral nerves or the muscle fibers. Some may be
hereditary, while others are acquired. Commonly rec-
ognized conditions fall into the categories of
myopathies, which are diseases of the muscle like
muscular dystrophy, disorders of the junction where
the nerve impulses are transmitted to the muscle like
myasthenia gravis, and neuropathies, which are dis-
eases of the peripheral nervous system like diabetic
neuropathy. 
The diagnosis of most neuromuscular diseases rest
on careful clinical evaluation of the patient, elec-
tromyography, the muscle biopsy, and in some
instances, molecular genetic studies.
Muscle biopsy, associated to histochemical and
immunohistological techniques, plays a key role in
diagnosis of many neuromuscular disorders. 
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A number of morphological abnormalities of mus-
cle can be recognized on histological stains such as
haematoxylin and eosin and Engel trichrome. This last
stain achieved  by W. King Engel (1963) is very
important in the identification of red staining struc-
tures such as rods, membranous myelin-like whorls of
rimmed vacuoles and  abnormal proliferation of mito-
chondria (the so called “Ragged Red Fibers”).
Histochemical techniques are essential for the
study of muscle biopsies for four main reasons. First,
they demonstrate the non-uniform nature of the muscle
highlighting the different biochemical properties of
specific fibre type and their selective involvement in
certain disease processes. Second, they may show an
absences of a particular enzyme. Third, an excess of a
particular substrate can be demonstrated. Fourth, they
may show structural changes in the muscle which
would not be apparent with routine histological stains,
such as the enzyme-deficient cores in central core dis-
ease "mouth-eaten" fibers, and abnormalities in the
distribution of mitochondria. In some neuromuscular
disorders there could be only non-specific myopatho-
logical features. However, a number of proteins,
including sarcolemmal, sarcomeric, and nuclear pro-
teins as well as enzymes with defects responsible for
neuromuscular disorders, have been identified during
the past two decades, allowing a more specific and
firm diagnosis of muscle diseases. Identification of
protein defects relies predominantly on immunohisto-
chemical preparations and on Western blot analysis.
While immunohistochemistry is very useful in identi-
fying abnormal expression of primary protein abnor-
malities in recessive conditions, it is less helpful in
detecting primary defects in dominantly inherited dis-
orders. Abnormal immunohistochemical expression
patterns can be confirmed by Western blot analysis
which may also be informative in dominant disorders,
although its role has yet to be established. Besides
identification of specific protein defects, immunohis-
tochemistry is also helpful in the differentiation of
inflammatory myopathies by subtyping cellular infil-
trates and demonstrating up-regulation of subtle
immunological parameters. This report will summa-
rize and describe the impact that histochemistry and
immunohistochemistry has had and the possibilities it
has opened up in the diagnosis of neuromuscular dis-
orders in human as well as in veterinary myology.
Histological and Histochemical Analysis
of Muscle Fibers 
A number of morphological abnormalities of muscle
can be recognized on histological stains such as
haematoxylin and eosin and Engel trichrome. 
In this last stain achieved  by W. King Engel (1963)
the muscle fibers stain a greenish-blue colour, and the
collagen is lighter. The nuclei stain red and the myelin
of the nerve stain a foamy red colour. Nerves my
appear poorly stained in the absence of myelin. Abnor-
mal accumulations of myofibrillar material may
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Table 1. Stains used in the diagnosis of selected neuromuscular disorders.
appear to be a paler green -blue colour and cytoplam-
ic bodies may appear more intensely stained. Engel
trichrome is very important in the identification of red
staining structures such as rods, membranous myelin-
like whorls of rimmed vacuoles and  abnormal prolif-
eration of mitochondria (the so called "Ragged Red
Fibers"). In Table 1 are reported additional stains
which may yield valuable insights into the pathogene-
sis of selected neuromuscular disorders.  
Histochemical techniques are essential for the
study of muscle biopsies in human as well as in veteri-
nary myology. Substantially there are three approach-
es to the histochemical analysis of the muscle fibers.
Those include the examination of the pattern of fiber
type; the measurement and recording of the diameters
of each fiber type and the analysis of the various
changes within individual fibers. Some of the most
used histochemical techniques are reported in table 1.
Further reference can be made to the excellent book on
muscle biopsy of Dubowitz and Sewry (2007).  
The pattern of fiber types can be studied accurately
only by subjecting cryostat-sectioned unfixed, frozen
muscle to myofibrillar adenosine triphosfatase (ATP)
reactions at pHs 4.3, 4.6 and 9.4. The different pH sen-
sitivity allows the differentiation of the fibers into four
types. The type 1 that are base-labile and acid stabile,
the type II fibers that possess the reverse properties.
Type 2B and 2C fibers display activity in solutions
containing a wider pH range than 2A and thus can be
differentiated. Type 2C fibers are rare in normal
human muscle but are present in developing muscle
and may appear under pathological circumstances. In
cat,  type-2C fibers represent, approximately, 2 to 3%
of the myofiber population [3]. 
In dog, masticatory muscles contain a unique adult
fiber type composition and different contractile protein
isoforms than do adult limb muscles.  In addition,
canine masticatory muscles are almostselectively
involved in an autoimmune disease, named Canine
Masticatory Muscle Myositis. Using histochemical
methods, the myofibrillar adenosine triphosphatase
(ATPase) staining of adult masticatory muscle resulted
in two populations of fibers. The majority of fibers are
stable after both acid and alkali preincubation, charac-
teristic of type 2C fibers, whereas the remaining fibers
are a variant of the type 1 fibers. However, further bio-
chemical and immunocytochemical investigation has
shown that the myofibrillar proteins of the masticatory
type 2 fibers differ from those of type 2C: fibers in limb
muscle. Hence, these fibers have been designated type
2M [4]. In animals the predominance of a fiber type is
characteristic of a particular muscle. In the soleus, for
example, type 1 fibers predominate; in the medial head
of the gastrocnemius muscle, type 2 fibers predominate.
In the anterior tibial muscle, two-thirds of the fibers are
type 2. By contrast, in the human muscle the three fibers
types occur in approximately identical proportions in a
pattern that not often varies. Therefore in any study that
assesses the distribution of the fiber types, it is neces-
sary to compare identical muscles and identical areas
(superficial versus deep) in a given muscle.
In certain congenital myopathies, the differentia-
tion into fiber types may be delayed or never appear
during development. This condition is called fiber-
type predominance and it is only rarely described in
foal (Paciello et al. 2008, unpublished data).
Fibers of some histochemical type may become
involved when a disease selectively or predominantly
affects the muscle of that type. Type 1 muscle fibers
involvement is often observed in certain congenital
myopathy instead type 2 muscle fibers atrophy can be
caused by: disuse; aging; weight loss; systemic dis-
ease, such as endocrinopathy; paraneoplastic syn-
drome and childhood myasthenia (Fig. 1).
The checkerboard pattern of fiber type is altered
also when denervated muscle is reinnervated. This
morphological aspect is due to collateral sprouting of
adjacent intact motor axons reinnervation of muscle
after denervation. Such a histochemical change is
termed fiber-type grouping. 
There are various oxidative enzyme reactions in use
to study muscle and some of them show similarity in the
appearance of the sections. With reduced nicotinamide
adenine dinucleotide-tetrazolium reductase (NADH-TR)
type 1 fibers are darker blue colour than type 2 fibers and
some type 2 are of intermediate intensity. This stain is
useful to study the intermiofibrillar network comprising
mitochondria and sarcoplasmic reticulum. Abnormal
internal fiber architecture is characteristic of target
fibers, often seen with acute denervation and reinnerva-
tion. Target fibers may have clear, dark, or loculated cen-
ters with central clear regions with mitochondrial stains
(Fig 2). Another example of abnormal internal architec-
ture are lobulated fibers that may occur in myopathy or
neuropathy Myopathies that commonly are associated
with lobulated fibers are: LGMD 2A; Ullrich Congenital
Muscular Dystrophy; Bethlem myopathy (Fig 3).
Succinic dehydrogenase  (SDH) and cytochrome
oxidase (COX) are purely mitochondrial enzymes. Sec-
tions stained for SDH have a bluish colour, it is the most
sensitive stain for detecting mitochondrial proliferation.
Muscle fibers with mitochondrial proliferation stain
darkly for SDH and are named "Ragged Blue Fibers"
(Fig 4). Staining for COX gives a brown end shade and
type I fibers stain more darkly than type II. On SDH,
COX- muscle fibers may be normal or have increased
staining. It is characteristic that COX negative muscle
fibers are present in mitochondrial myopathy (Fig 5).
To stains glycogen and polysaccharides the gold
standard method stain is Periodic acid Schiff (PAS)
that stain fibers in a deep-pink colour and highlights
the intermyofibrillar network pattern. The specificity
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of the stain for glycogen can be checked by digestion
with α-amylase prior to PAS staining. Polysaccharide
storage myopathy is a common disorder of many
breeds of horses and ponies [5]. 
Oil red O (ORO) and Sudan Black  stains lipid in
red and black respectively. The intracellular lipid
droplets of the fibers appear as a fine red (ORO) or
black (Sudan black) dots of variable size and they are
more abundant in type 1 fibers than in type 2. 
In disorders affecting lipid metabolism, the exces-
sive accumulation of lipid shows up as larger and more
extensive droplets (Fig. 6).
Amyloid can be demonstrated in certain pathologi-
cal condition within muscle fibers using Congo red
stain. With this method amyloid is visible as a red
deposit with normal bright field optics but also shows
'apple-green' birefringence with polarized light. An
excellent method to enhanced  the positivity is using
fluorescence with an excitation filter suitable for fluo-
rochromes such as Texas Red [6] . 
Diagnostic Immunohistochemistry
Since the introduction of histochemical techniques in
the 1960s, immunohistochemistry in the 1980s has had
the most significant effect upon the interpretation of
muscle biopsies. Overall, it is important to mention that,
as for enzyme histochemical preparations, muscle spec-
imen preservation by freezing is a prerequisite for accu-
rate immunohistochemical and for immunoblot analysis
as there are only a limited number of antibodies (espe-
cially against sarcolemmal proteins) that work on paraf-
fin sections. Beside identification of specific protein
defects, immunohistochemistry has turned out to be
helpful also in the diagnosis of inflammatory myopathy.
A number of proteins, including sarcolemmal, sar-
comeric, and nuclear proteins with defects responsible
for neuromuscular disorders, have been identified dur-
ing the past two decades, allowing a more specific and
firm diagnosis of muscle diseases. Identification of
protein defects relies predominantly on immunohisto-
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Fig. 1. Type II muscle fibers atrophy
in a case of Cushing syndrome (Origi-
nal magnification 20×). Fig. 2. Target
fibers stained with NADH-TR . (Orig-
inal magnification 40×). Fig. 3. Lobu-
lated muscle fibers stained with
NADH-TR. (Original magnification
40×). Fig 4. Fibers with abnormal
mitochondria intensely stained for
SDH (Original magnification 40×).
Fig. 5. Fiber devoid of COX activity
appear white compared with the fiber
typing pattern of adjacent fibres (COX
stain Original magnification 40×).
Fig. 6. Accumulation of lipid in a
"lipid storage myopathy " (ORO stain
Original magnification 40×).
chemical preparations and on Western blot analysis.
Abnormal immunohistochemical expression patterns
can be confirmed by Western blot analysis which may
also be informative in dominant disorders, although its
role has yet to be established
Immunohistochemistry
and Immunofluorescence 
Immunohistochemical  preparations are relatively sim-
ple to perform and represent a standard method in neu-
romuscular laboratories. There are numerous immuno-
histochemical methods that may be used to demon-
strate specific protein. Immunohistochemistry  consist
in the localization of antigens in tissue sections by the
use of antibodies as specific reagents through antigen-
antibody interactions. This antibody-antigen complex
is bound by a secondary, enzyme-conjugated antibody.
Several techniques can be used to enhance the staining
by forming a complex of peroxidase-antiperoxidase,
avidin-biotin-peroxidase or avidin-biotin alkaline
phosphatase. Finally, in the presence of substrate or
chromogens, the enzymes form a coloured deposit at
the site of the antigen-antibody complex. The colour of
the deposit depends on the chromogen used. 
There are several mono- and polyclonal antibodies
commercially available that work on human as well as
in several other animal species, and  numerous detec-
tion systems.
Similar to immunohistochemistry, immunofluores-
cence can be used to detect the location and relative
quantity of an antigen on muscle fibers. The technique
use a fluorescent dye that is covalently attached to the
primary or secondary antibody. When a light illumi-
nates the fluorescent dye, the light is absorbed and the
dye emits a different colour light which is visible
under the microscope. Direct immunofluorescence
requires only one single-step incubation with directly
conjugated antibodies, while indirect immunofluores-
cence uses unconjugated primary antibodies which are
labelled by fluorescently conjugated secondary anti-
bodies in a second-step.
Western  blots
Western blots are used to detect the proteins in homog-
enized skeletal muscle samples by using specific anti-
bodies. It gives information about the presence and the
relative amount of that proteins, compared with a con-
trol. The proteins of the sample are electrophoresed
into a gel and separated based upon molecular weight
and charge. In the blotting process, they are transferred
onto a membrane made of nitrocellulose or PVDF by
applying a current. To detect the antigen blotted on the
membrane, a primary antibody is incubated with the
membrane and then labelled by a secondary enzyme
conjugated antibody. Finally, the enzyme substrate is
added which will precipitate upon reaction with the
conjugate so that the position of the membrane-bound-
primary antibody will become visible. Size approxi-
mations can be done by comparing the stained band
with that of a prestained protein size marker.
Muscular dystrophies
Muscular dystrophies in animals are relatively uncom-
mon and may be difficult to diagnose. A correct diag-
nosis is very important as the prognosis differs for the
various muscle diseases. For most disorders that have
been identified, neither a cure nor a specific therapy is
yet available. Pharmacologic as well as cell and gene
therapies that are being developed for similar human
diseases may be used; and animals could be important
models for clinical trials.
Since identification of the dystrophin gene muta-
tion and protein defect responsible for progressive
muscular dystrophy types Duchenne and Becker in
1987 [7] ,  many other protein defects have been iden-
tified allowing further classification and accurate diag-
nosis of muscular dystrophies [8].  These gene muta-
tions and protein defects are subtyped in sarcolem-
mopathies with sarcolemmal protein deficiencies and
in non-sarcolemmal muscular dystrophies with defects
of nuclear, i.e. emerin, and sarcomeric proteins, i.e.
myotilin and telethonin, as well as enzymes, i.e. cal-
pain 3, and can be documented by immunohistochem-
istry and by immunoblot analysis. 
Until recently, in veterinary medicine, only one
form of muscular dystrophy have been detected, most
likely, many of the same types of muscular dystrophy
that occur in human beings also occur in companion
animals. 
In immunohistochemical examination, which
alongside Western blot analysis are the gold standard
in diagnosis of muscular dystrophies, the proteins
show typical sarcolemmal expression patterns which
cannot be distinguished among the different proteins.
Loss or reduction of one of these sarcolemmal pro-
teins results in increased fragility of the sarcolemma
with destructive effects due to tension generated
especially during contraction and exercise [9,10]
which may lead to muscle fibre necrosis and apopto-
sis with subsequent muscle fibre loss and fibrosis. As
the integrity of the entire dystrophin-glycoprotein
complex is largely interdependent on each of its pro-
teins, defects of one protein may be associated with
secondary reduction or absence of other proteins, e.g.
secondary loss of sarcoglycans due to primary dys-
trophin defects [11,12] . To exclude secondary
absence of sarcolemmal proteins due to muscle fibre
degeneration or necrosis inclusion of a control reac-
tion for spectrin is recommended.
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Dystrophinopathy
Duchenne muscular dystrophy (DMD )associated with
an absence of dystrophy and genetic mutation of the
dystrophin gene is the most common and best studied
of the muscular dystrophy in human beings and com-
panion animals. In people, a less common and milder
form (BMD) shows present but abnormal dystrophin.
To date, BMD has not been identified in animals but
likely occurs. In Duchenne like muscular dystrophy,
there is a complete lack of normal dystrophin both in
immunohistochemical and immunoblots study as
mutations are out-of-frame mutations resulting in an
early termination of protein synthesis due to newly
created stop codons and an incomplete protein which
cannot be bound and fixed onto the sarcolemma (Fig 7).
Occasionally, can be seen revertant fibres which dis-
play immunoreactivity with antibodies to all or some
domains and which are thought to arise by second site
in-frame deletions which partly restore the reading
frame (Fig 7) [13,14]. 
In immunohistochemical examination, antibodies
against present and intact domains of the dystrophin
molecule display regular sarcolemmal expression pat-
terns while reactions with antibodies against the miss-
ing domains remain negative. In Western blot analysis,
the usually smaller truncated molecule shows an
increased migration; however, less frequently, duplica-
tion of the gene causes an elongated dystrophin mole-
cule with a decreased migration capacity. 
Primary dystrophinopathy affects typical secondary
reduction or loss of sarcoglycans in immunohisto-
chemical preparations as well as in Western blots. This
reduction is most striking in Duchenne muscular dys-
trophy and milder in the Becker type; in carriers of a
dystrophinopathy the secondary reduction of the
sarcoglycan subunits correlates with the dystrophin
expression pattern and level in the individual carrier.
While sarcoglycans as proteins of the dystrophin-
glycoprotein complex are down-regulated, utrophin, a
395-kDa protein with considerable homology to dys-
trophin, is up-regulated, which is suggested to be asso-
ciated with muscle fibre regeneration and may com-
pensate for dystrophin deficiency  [15,16].
Muscular Dystrophy with Merosin
(Laminin α2) deficiency 
Approximately 50% of human CMD patients have a
deficiency of merosin (laminin α2) expression in mus-
cle. Laminin α2 is the major component of the basal
lamina that surrounds each muscle fiber. It is one of the
extracellular ligands for the dystrophin-associated gly-
coprotein complex; it links dystrophin to the extracellu-
lar matrix and contributes to the stability of the muscle
basement membrane. Therefore, analogous to dys-
trophinopathies, the use of two antibodies against dif-
ferent fragments of the laminin a-chain is recommended
recognizing a 300-kDa fragment towards the N-termi-
nus and a 80-kDa fragment towards the C-terminus. A
defect of merosin which is closely associated with the
sarcolemmal dystrophin-glycoprotein complex causes a
defective or focally absent basal lamina which mediates
injury of the sarcolemma [17]. In contrast to defects of
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Fig. 7. Duchenne muscular dystrophy
(a, b, c) with expression of dystrophin
lacking, except in some 'revertant
fibres' (d, arrow). Avidin-biotin-perox-
idase complex method with Mayer's
hematoxylin counterstain. Original
magnifications 20× for all figures.
dystrophin or sarcoglycan subunits, defective expres-
sion of merosin causes no secondary defects or reduc-
tions in the expression of dystrophin or sarcoglycans.
As merosin is lacking not only in muscle but also in
neural structures of the skin, skin biopsy provides a
diagnostic alternative to muscle biopsy. However, dif-
ferential diagnosis concerning other muscular dystro-
phies with sarcolemmal defects is not possible on epi-
dermal tissue if the suspected merosin defect cannot be
confirmed [18].
Congenital muscular dystrophy associated with
absence of laminin α2 has been described in a young
female Brittany-Springer Spaniel mixed breed dog
[19]and in cats [20, 21].
Sarcoglycanopathies
In humans, mutations in the components of the sarco-
glycan (SG) complexes (α,β,γ and δ-SG) typically
cause severe forms of limb girdle muscular dystrophy
[22,23]. Numerous missense, splicing, and nonsense
mutations have been identified in all four of the SG
genes. Mutations in the fifth member of the sarcogly-
can family,  -SG, causes amyoclonus-dystonia syn-
drome [24].
A genotype-phenotype correlation in sarcogly-
canopathies is very difficult because onset and
progress are variable even with the same mutation and
within the same family [12]. As has been mentioned
for the whole dystrophin-glycoprotein complex, the
integrity of the entire sarcoglycan complex is also
interdependent on each of its components. Theoreti-
cally, the mutant subunit is lacking; however, muta-
tions of one of the sarcoglycan subunits cause second-
ary reduction or absence of any of the other sarcogly-
can components in immunohistochemical preparations
as well as in immunoblots. Sometimes there is a typi-
cal immunohistochemical expression pattern with pri-
mary β- and δ-sarcoglycan defects causing complete
lack of the other subunits, while primary α- and γ-
defects allow small remnants of the other sarcoglycan
proteins (Fig 8). However, it is usually impossible to
assess the primary defective subunit. Furthermore,
Western blot analysis has been described to be techni-
cally difficult because the subunits are intermixed with
and concealed by various cytoplasmic proteins with
similar molecular weights and isoelectric points to
those of each sarcoglycan subunit. As it is also virtual-
ly impossible to make a diagnosis of any specific
sarcoglycan defect based solely on the clinical find-
ings, genetic testing is required to differentiate
between the sarcoglycanopathies [25].
While specific mutations have not yet been identi-
fied in any canine sarcoglycanopathies, SG-deficien-
cies have been identified in a young Boston Terrier,
Cocker Spaniel, and Chihuahua [26]. Indirect
immunofluorescence staining of muscle biopsy speci-
mens from the three different breeds of dogs using
monoclonal β and γ-SG and polyclonal α-SG antibod-
ies showed varying patterns of SG loss. As so few
cases have been identified in this species, a compari-
son of the incidence with that in humans cannot yet be
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Fig. 8. Sarcoglycanopathy with
reduced expression of  γ- (a) and
absence of β-sarcoglycan (b). Avidin-
biotin-peroxidase complex method
with Mayer's hematoxylin counter-
stain. Original magnifications 20× for
all figures.
Fig. 9. Polymyositis with infiltration
of predominantly T cells, identificated
as CD3 (a) and CD4 (b). Avidin-
biotin-peroxidase complex method
with Mayer's hematoxylin counter-
stain. Original magnifications 20× for
all figures. 
given. Sarcoglycan deficiencies have not yet been
identified in the cat but are likely to exist. [26].
Dystroglycan deficiency 
Recent studies have identified a number of forms of
muscular dystrophy, termed dystroglycanopathies,
which are associated with loss of natively glycosylat-
ed alpha-dystroglycan. These disorders have been
recently described in Sphynx and Devon Rex cats.
Affected cats displayed a slowly progressive myopa-
thy with clinical and histologic hallmarks of muscular
dystrophy including skeletal muscle weakness with no
involvement of peripheral nerves or CNS. Skeletal
muscles had myopathic features and reduced expres-
sion of alpha-dystroglycan, while beta-dystroglycan,
sarcoglycans, and dystrophin were expressed at nor-
mal levels. In the Sphynx cat, analysis of laminin and
lectin binding capacity demonstrated no loss in overall
glycosylation or ligand binding for the alpha-dystro-
glycan protein, only a loss of protein expression. A
reduction in laminin-alpha2 expression in the basal
lamina surrounding skeletal myofibers was also
observed. Reduction in the levels of glycosylated
alpha-dystroglycan by immunoblot was also identified
in an affected Devon Rex cat [27].
Inflammatory myopathies 
Another group of neuromuscular disorders where
immunohistochemistry is very helpful in diagnosis and
differential diagnosis is inflammatory myopathies, dis-
playing a typical morphological features in distribu-
tion and proportions of inflammatory infiltrates which
can easily be identified by immunohistochemical typ-
ing of infiltrating mononuclear cells (Fig 9).
In addition to typing of immunocompetent infiltrat-
ing cells which is predominantly helpful in differenti-
ation of myositis subtypes, there have been great
efforts to find other markers that are indicative of an
immunological muscle disease. This is of special
importance, as up to 20% of patients with inflammato-
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Fig. 10. Scheme to explain the anergization of muscle fibers and the expression
of MHC class I also faraway that inflammatory cells. 
Fig. 11. Expression of  MHC class I (a)
and MHC class II (b) on muscle fibers in
CMMM. Original magnifications 400×.
Nuclei counterstained with iodure pro-
pidium.
ry muscle disease lack any inflammatory cellular infil-
trate in their first muscle biopsy, thus presenting a
false-negative result. Further immunological parame-
ters which are up-regulated in inflammatory muscle
diseases are cell adhesion molecules and cytokines.
Classical examples of cell adhesion molecules are
MHC class I molecules binding T8 cells as well as
MHC II molecules binding T4 cells.212-214 MHC
class I molecules are usually extensively up-regulated
in inflammatory myopathies (Fig 10). They are
expressed by inflammatory cells and muscle fibres and
represent a necessity for cytotoxic attacks by T8 lym-
phocytes. MHC class I + muscle fibres may display
sarcolemmal as well as sarcoplasmic expression (Fig
11) [28].  
Finally immunoistochemistry/immunofluorescence
can be used to identify specific etiological agents such
as Leishmania spp. (Fig 12), Neospora caninum  (Fig
13) or Toxoplasma gondi that can cause inflammatory
myopathies in animal as well as in human [29, 30] .
Conclusion and future perspectives
Many of the other forms of muscular dystrophy iden-
tified in human medicine have not yet been discov-
ered in animals. However, most if not all forms of
muscular dystrophy in humans are certain to exist in
other species; one just has to know how to recognize
them.
Identification of protein defects by immunohisto-
chemical as well as Western blot analysis allows a spe-
cific and firm diagnosis in a wide range of muscular
dystrophies. 
However, it is likely that in these disorders also,
immunocytochemical analysis may widen the under-
standing of muscle fibre pathology as well as help in
the development of therapeutic strategies.
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